Bedinvetmab is the key medicinal component of the licensed veterinary products Beransa and Librela. The monoclonal antibody targets the 13 kDa protein, nerve growth factor (NGF). By inhibiting NGF from interacting with its receptors, Bedinvetmab prevents the activation of pain pathways thereby providing analgesia to arthritic dogs. The novel use of antibodies for the treatment of pain could be used to mask injury in racing animals. To control misuse in the greyhound racing industry an ELISA screen capable of detecting Bedinvetmab down to 1.25 ng/mL in canine plasma was developed. Positive samples could be confirmed by LC-MS/MS down to a level of 62.5 ng/mL in canine plasma